DE9315698U1
(de)
*
|
1993-10-14 |
1993-12-23 |
BÜCHI LABORATORIUMS-TECHNIK AG, Flawil |
Verdampfer-Kolben für einen Rotationsverdampfer
|
AU2002250143A1
(en)
*
|
2001-03-16 |
2002-10-03 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
CA2633171C
(fr)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Compositions et procedes destines au diagnostic et au traitement de tumeurs
|
US20030068691A1
(en)
*
|
2001-07-16 |
2003-04-10 |
Applera Corporation |
Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
|
CA2458818A1
(fr)
*
|
2001-08-30 |
2003-04-10 |
Nuvelo, Inc. |
Procedes et materiaux relatifs aux polynucleotides et polypeptides de type facteur de croissance de cellules souches
|
MXPA04003057A
(es)
|
2001-10-04 |
2005-06-20 |
Immunex Corp |
Proteina 4 de enlace ul16.
|
EP1562969A4
(fr)
|
2002-03-28 |
2006-07-05 |
Bristol Myers Squibb Co |
Nouvelle proteine de surface cellulaire avec replis d'hemoglobine, bgs-19
|
ES2307933T3
(es)
*
|
2002-04-26 |
2008-12-01 |
Astellas Pharma Inc. |
Proteina de 35 kda.
|
WO2004005335A2
(fr)
*
|
2002-07-05 |
2004-01-15 |
Borean Pharma A/S |
Hormone de croissance multimerisee
|
ATE493433T1
(de)
|
2002-09-11 |
2011-01-15 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
WO2004031411A2
(fr)
|
2002-09-30 |
2004-04-15 |
Oncotherapy Science, Inc. |
Genes et polypeptides associes aux cancers du pancreas chez l'homme
|
EA010055B1
(ru)
|
2003-03-19 |
2008-06-30 |
Байоджен Айдек Ма Инк. |
ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
|
WO2005030955A1
(fr)
*
|
2003-09-29 |
2005-04-07 |
Chugai Seiyaku Kabushiki Kaisha |
Proteine exprimee dans une cellule nk
|
ATE423200T1
(de)
*
|
2003-10-30 |
2009-03-15 |
Kazusa Dna Res Inst Foundation |
Neues plexin-polypeptid, dieses codierende dna und verwendung davon
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
WO2005072419A2
(fr)
*
|
2004-01-27 |
2005-08-11 |
Nuvelo, Inc. |
Facteur proliferatif gastro-intestinal et utilisations de celui-ci
|
GB0403491D0
(en)
*
|
2004-02-17 |
2004-03-24 |
Univ Cambridge Tech |
Polypeptides, methods and means
|
US20050186577A1
(en)
|
2004-02-20 |
2005-08-25 |
Yixin Wang |
Breast cancer prognostics
|
US7901881B2
(en)
|
2004-04-09 |
2011-03-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Diagnostic tool for diagnosing benign versus malignant thyroid lesions
|
CA2567520A1
(fr)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Conjugues anticorps-maytansinoides
|
RS52593B
(en)
|
2004-06-24 |
2013-04-30 |
Biogen Idec Ma Inc. |
TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
|
WO2006008294A2
(fr)
*
|
2004-07-23 |
2006-01-26 |
Evotec Neurosciences Gmbh |
Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
EP3088004B1
(fr)
|
2004-09-23 |
2018-03-28 |
Genentech, Inc. |
Anticorps et conjugués modifiés au niveau des cystéines
|
CA2607291A1
(fr)
|
2005-05-12 |
2006-11-23 |
Steven D. Levin |
Compositions et procedes permettant de moduler des reponses immunitaires
|
SG10201508322SA
(en)
|
2005-07-08 |
2015-11-27 |
Biogen Ma Inc |
Sp35 antibodies and uses thereof
|
DK1937815T3
(en)
|
2005-09-13 |
2015-08-03 |
Nat Res Council Canada |
Methods and compositions for the modulation of tumor cell activity
|
GB0522113D0
(en)
*
|
2005-10-28 |
2005-12-07 |
Ares Trading Sa |
vWFA-domain containing proteins
|
GB0525999D0
(en)
*
|
2005-12-21 |
2006-02-01 |
Ares Trading Sa |
Novel members of the kazal family of serine protease inhibitors
|
GB0615287D0
(en)
*
|
2006-08-01 |
2006-09-06 |
Ares Trading Sa |
Integral membrane protein
|
JP2010505868A
(ja)
*
|
2006-10-02 |
2010-02-25 |
ザ スクリプス リサーチ インスティチュート |
エーテル脂質シグナル伝達経路を制御する酵素
|
GB0620735D0
(en)
*
|
2006-10-18 |
2006-11-29 |
Ares Trading Sa |
Proteins
|
DK2173379T3
(en)
|
2007-07-02 |
2015-12-07 |
Oncomed Pharm Inc |
Compositions and methods for treatment and diagnosis of cancer
|
GB0805159D0
(en)
|
2008-03-19 |
2008-04-23 |
Sancho Madrid David |
Immune modulation via C-type lectin
|
WO2009026660A1
(fr)
|
2007-08-30 |
2009-03-05 |
Walter And Eliza Hall Institute Of Medical Research |
Marqueur de cellules dendritiques et son utilisation
|
ES2908934T3
(es)
|
2007-10-04 |
2022-05-04 |
Zymogenetics Inc |
ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
EP2217697B1
(fr)
*
|
2007-11-08 |
2015-06-10 |
Biogen MA Inc. |
Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
|
AU2009233708B2
(en)
|
2008-04-09 |
2015-06-04 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP2011519959A
(ja)
*
|
2008-05-13 |
2011-07-14 |
ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
破壊された細胞膜を有する細胞、病原体に感染した細胞、死にかけている細胞または死細胞を検出する方法
|
EP2315779A2
(fr)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprenant des anticorps anti-lingo ou leurs fragments
|
US8227417B2
(en)
|
2008-07-25 |
2012-07-24 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
|
MX2011008044A
(es)
|
2009-02-03 |
2012-01-12 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre.
|
US9752124B2
(en)
|
2009-02-03 |
2017-09-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising the stem cells
|
EP2412800A1
(fr)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir
|
AU2010268690B2
(en)
|
2009-07-03 |
2011-11-10 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
WO2011004404A1
(fr)
*
|
2009-07-10 |
2011-01-13 |
Decode Genetics Ehf |
Variantes génétiques pour prédire le risque de glaucome
|
EP2475391B1
(fr)
|
2009-09-09 |
2018-09-12 |
Centrose, LLC |
Conjugués médicamenteux ciblés à visée extracellulaire
|
AU2010324506B2
(en)
|
2009-11-24 |
2015-02-26 |
Alethia Biotherapeutics Inc. |
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
|
WO2011075786A1
(fr)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugués et leurs méthodes de production
|
CN102933236B
(zh)
|
2010-04-15 |
2014-10-08 |
斯皮罗根有限公司 |
吡咯并苯二氮卓类及其结合物
|
CN103068406B
(zh)
|
2010-06-08 |
2017-06-30 |
基因泰克公司 |
半胱氨酸改造的抗体和偶联物
|
PE20171640A1
(es)
|
2010-09-22 |
2017-11-09 |
Alios Biopharma Inc |
Analogos de nucleotidos sustituidos
|
CN103313990B
(zh)
|
2010-11-17 |
2016-07-20 |
基因泰克公司 |
丙氨酰美登醇抗体偶联物
|
EP3103810A3
(fr)
|
2011-04-21 |
2017-03-08 |
Garvan Institute of Medical Research |
Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
|
CN103608684B
(zh)
|
2011-05-12 |
2016-05-04 |
基因泰克公司 |
利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
|
CA2841745A1
(fr)
|
2011-07-15 |
2013-01-24 |
Oncomed Pharmaceuticals, Inc. |
Agents de fixation aux proteines rspo et leurs utilisations
|
HUE025661T2
(en)
|
2011-10-14 |
2016-04-28 |
Medimmune Ltd |
Pyrrolobenzodiazepines and their conjugates
|
CA2860234A1
(fr)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Analogues de nucleotide phosphorothioate substitue
|
NZ626742A
(en)
|
2012-02-22 |
2016-06-24 |
Alethia Biotherapeutics Inc |
Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
|
WO2013130093A1
(fr)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
|
NZ631601A
(en)
|
2012-03-21 |
2016-06-24 |
Alios Biopharma Inc |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
EA032038B1
(ru)
|
2012-07-13 |
2019-03-29 |
Онкомед Фармасьютикалс, Инк. |
Rspo3-связывающие агенты и их применение
|
MX364329B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina.
|
NZ707490A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
KR101995620B1
(ko)
|
2012-10-12 |
2019-07-03 |
에이디씨 테라퓨틱스 에스에이 |
피롤로벤조디아제핀-항체 컨주게이트
|
RS57694B1
(sr)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Pirolobenzodiazepin - anti-psma konjugati antitela
|
WO2014096365A1
(fr)
|
2012-12-21 |
2014-06-26 |
Spirogen Sàrl |
Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
|
EP2935268B2
(fr)
|
2012-12-21 |
2021-02-17 |
MedImmune Limited |
Pyrrolobenzodiazépines et conjugués associés
|
CA2904044C
(fr)
|
2013-03-13 |
2020-03-31 |
Medimmune Limited |
Pyrrolobenzodiazepines et leurs conjugues
|
EP2968596B1
(fr)
|
2013-03-13 |
2019-03-06 |
Medimmune Limited |
Pyrrolobenzodiazépines et leurs conjugués
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
CA2918139A1
(fr)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054985B1
(fr)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Conjugués anticorps-pyrrolobenzodiazépine
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2015052535A1
(fr)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Conjugués anticorps-pyrrolobenzodiazépine
|
WO2015095223A2
(fr)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
|
WO2015095212A1
(fr)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
EP3191134B1
(fr)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP2017528523A
(ja)
|
2014-09-16 |
2017-09-28 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
線維性疾患の治療
|
MA40575A
(fr)
|
2014-09-17 |
2016-03-24 |
Genentech Inc |
Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN107206101B
(zh)
|
2014-12-03 |
2021-06-25 |
基因泰克公司 |
季铵化合物及其抗体-药物缀合物
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
EP3353210B1
(fr)
|
2015-09-25 |
2024-11-06 |
Genentech, Inc. |
Anticorps anti-tigit et méthodes d'utilisation
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017165734A1
(fr)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
EP3458101B1
(fr)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Conjugués anticorps-protac et procédés d'utilisation
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
EP3464280B1
(fr)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2018115879A1
(fr)
|
2016-12-21 |
2018-06-28 |
Mereo Biopharma 3 Limited |
Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
ES2871001T3
(es)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
JP2020517609A
(ja)
|
2017-04-18 |
2020-06-18 |
メディミューン リミテッド |
ピロロベンゾジアゼピン複合体
|
BR112019021880A2
(pt)
|
2017-04-20 |
2020-06-02 |
Adc Therapeutics Sa |
Terapia de combinação com conjugado anticorpo anti-axl-droga
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
RS62928B1
(sr)
|
2017-08-18 |
2022-03-31 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
MX2020003089A
(es)
|
2017-09-20 |
2020-10-15 |
Ph Pharma Co Ltd |
Analogos de tailanstatina.
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3841123A2
(fr)
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anticorps anti-tigit
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
CA3115110A1
(fr)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Inducteurs chimiques conjugues de degradation et methodes d'utilisation
|
EP3894427A1
(fr)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
GB202211117D0
(en)
*
|
2022-07-29 |
2022-09-14 |
Replay Holdings Llc |
Compositions and methods for non-immunogenecity
|
WO2024138128A2
(fr)
|
2022-12-23 |
2024-06-27 |
Genentech, Inc. |
Conjugués d'agent de dégradation de céréblon et leurs utilisations
|
WO2024220546A2
(fr)
|
2023-04-17 |
2024-10-24 |
Peak Bio, Inc. |
Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires
|